Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Today tags : Approval save search
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Published: 2024-04-23 (Crawled : 20:00) - globenewswire.com
DAWN S | $16.65 8.26% 7.63% 6.6M
|
Professional, Scientific, and T...
| Email alert
Add to watchlist
day fda approval tumor for
Aemetis to Present to Institutional Investors at UBS, JP Morgan and Stifel Conferences to Review Recent Federal Approval of $200 Million of EB-5 Funding for SAF, Biogas, and CCS Projects
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
AMTX | $3.89 7.31% 6.81% 1.2M
|
Process Industries
|
| O: -1.3%
H: 2.9%
C: 2.9%
approval review million for funding
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $139.22 6.32% 5.95% 200K
|
Health Technology
|
| O: 3.5%
H: 4.77%
C: 2.39%
lung approval cancer cell treatment for
Todays' Top-5
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $5.48 10.93% 9.85% 31M
|
Manufacturing
|
| O: 16.59%
H: 0.65%
C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.